Hello MSWorld Members,

Welcome to our new home! We hope you love it as much as we do!

we promise.

to offer current and relevant information.

to grow a community built on positive and affirming support.

to showcase member creativity.

to provide safe chat rooms.

to provide well moderated forums.

we believe that what we give as a community comes back to us.

welcome to MSWorld on this journey through a different lens. together. we are msworld.
we are. community.

We appreciate your understanding as we finalize our new home. Our arcade is still currently under construction and won’t be available for a while. Thank you for your patience while we prepare a new and improved arcade for you.

enjoy our new home.

support reimagined.
See more
See less

Plegridy Update from AAN 2016

  • Filter
  • Time
  • Show
Clear All
new posts

    Plegridy Update from AAN 2016

    At the US Food and Drug Administration (FDA)–approved every-2-weeks dosing schedule, peginterferon β-1a (Plegridy, Biogen Idec) maintains efficacy for up to 6 years in adults with relapsing-remitting multiple sclerosis (RRMS), new long-term data suggest.

    Over 6 years, the adjusted ARR was significantly improved with peginterferon β-1a every 2 weeks compared with the -4-weeks regimen (0.188 vs 0.263; rate ratio, 0.714; 95% confidence interval, 0.563 - 0.904; P = .0052). Year-over-year adjusted ARRs were generally reduced in the every-2-weeks group.

    Tried to go to this hyperlink, but had to Sign Up for something. Guess I will research it on my own, but thanks for posting it
    Peace to all,
    RRMS 11/11/2005, SPMS 20011 (guess I 'graduated')